Lassa fever

Oracle and Oxford Nanopore Team Up to Improve Healthcare and Speed Discovery of New Medical Breakthroughs

Retrieved on: 
Thursday, September 16, 2021
Cloud, Form, Biology, Drug discovery, Form 10-K, Java, Drug development, Technology, Health, OCI, Oracle Cloud, Dengue fever, Private Securities Litigation Reform Act, Genomics, View, NYSE, Solution, COVID-19, Multimedia, Nanopore sequencing, Public health, MySQL, Lassa fever, Risk, Organization, Cloud computing, SEC, Oracle Corporation, Vaccine, Software, Antibiotics

Oracle and Oxford Nanopore have recently begun a collaboration to jointly explore several potential new solutions that would use genomic sequencing running on Oracle Cloud Infrastructure (OCI) to help speed medical breakthroughs and improve patient care.

Key Points: 
  • Oracle and Oxford Nanopore have recently begun a collaboration to jointly explore several potential new solutions that would use genomic sequencing running on Oracle Cloud Infrastructure (OCI) to help speed medical breakthroughs and improve patient care.
  • Leveraging the high performance, security, and extensive reach of Oracle Cloud, Oracle and Oxford Nanopore will have the ability to extend population-scale genetic sequencing across the globe.
  • In parallel, Oracle has committed to investing 150 million in Oxford Nanopore, subject to customary conditions.
  • Oracle offersintegrated suites of applications plus secure, autonomous infrastructure in the Oracle Cloud.For more information about Oracle (NYSE: ORCL), please visit us at oracle.com .

EDCTP and CEPI Funding Moves IAVI's Lassa fever Vaccine Candidate Into Advanced Clinical Development

Retrieved on: 
Tuesday, June 15, 2021
AIDS, Health, Other Health, General Health, Clinical trials, Research, Science, Medical specialties, Clinical medicine, Medicine, Ebola, Breakthrough therapy, Vaccines, West African Ebola virus epidemic, Lassa fever, Ebola vaccine, rVSV-ZEBOV vaccine, Vaccine, Lassa, Lassa Fever, EDCTP, CEPI, IAVI, LASSA FEVER, EDCTP, CEPI, IAVI

Despite this disease burden, which is believed to be significantly underestimated, no vaccine for Lassa fever is currently available.

Key Points: 
  • Despite this disease burden, which is believed to be significantly underestimated, no vaccine for Lassa fever is currently available.
  • The joint award supports an international collaboration, called Lassa Fever Vaccine Efficacy and Prevention for West Africa (LEAP4WA), to conduct a Phase IIb clinical trial of IAVIs Lassa fever vaccine candidate among adults and children in Liberia, Nigeria, and Sierra Leone.
  • LEAP4WA builds on an existing partnership with CEPI that supports IAVI and a global consortium of partners to conduct Phase I and II clinical trials of IAVIs Lassa fever vaccine candidate.
  • We are excited to apply the recombinant VSV technology, used in the previously licensed Ebola vaccine called ERVEBO, for the development of a much-needed Lassa fever vaccine.

Kineta Presents Clinical Study Results of LHF-535 at the International Conference on Antiviral Research (ICAR)

Retrieved on: 
Thursday, March 25, 2021
Health sciences, Health, Medical specialties, Clinical research, Drug discovery, Pharmaceutical industry, Lassa fever, International Society for Antiviral Research, Clinical trial

SEATTLE, March 25, 2021 /PRNewswire/ -- Kineta, Inc., a clinical stage biotechnology company focused on the development of novel immunotherapies, announced today the presentation of new clinical data on LHF-535 at the International Conference on Antiviral Research (ICAR) Virtual Conference 2021.

Key Points: 
  • SEATTLE, March 25, 2021 /PRNewswire/ -- Kineta, Inc., a clinical stage biotechnology company focused on the development of novel immunotherapies, announced today the presentation of new clinical data on LHF-535 at the International Conference on Antiviral Research (ICAR) Virtual Conference 2021.
  • Sean Amberg, PhD, Director of Biodefense Initiatives at Kineta, presented the clinical data establishing the safety, tolerability, and pharmacokinetic profile of LHF-535.
  • "We are encouraged by these positive clinical study results for LHF-535 as there are no therapeutic options for patients infected with Lassa fever.
  • Kineta, Inc. is a clinical stage biotechnology company committed to developing disruptive life science technologies that address unmet patient needs.

Lassa Hemorrhagic Fever - Global Pipeline Review 2020 - ResearchAndMarkets.com

Retrieved on: 
Tuesday, April 21, 2020
Infectious diseases, Pharmaceutical, Health, Infectious diseases, Medical specialties, Medicine, Tropical diseases, Zoonoses, Biological weapons, Lassa fever, RTT, Lassa, Viral hemorrhagic fever

The "Lassa Fever (Lassa Hemorrhagic Fever) - Pipeline Review, H1 2020" drug pipelines has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Lassa Fever (Lassa Hemorrhagic Fever) - Pipeline Review, H1 2020" drug pipelines has been added to ResearchAndMarkets.com's offering.
  • This Pharmaceutical and Healthcare disease pipeline guide provides an overview of the Lassa Fever (Infectious Disease) pipeline landscape.
  • The pipeline guide also reviews of key players involved in therapeutic development for Lassa Fever (Lassa Hemorrhagic Fever) and features dormant and discontinued projects.
  • Formulate corrective measures for pipeline projects by understanding Lassa Fever (Infectious Disease) pipeline depth and focus of Indication therapeutics.

Themis Bioscience and CEPI Announce Initiation of Phase 1 Clinical Trial with Lassa Fever Vaccine

Retrieved on: 
Tuesday, October 29, 2019
Science, Other Science, Biotechnology, Research, Pharmaceutical, Health, Infectious diseases, Clinical trials, Medical specialties, Infectious diseases, Medicine, Coalition for Epidemic Preparedness Innovations, Epidemics, Tropical diseases, Biological weapons, Zoonoses, RTT, Lassa fever, Lassa, Vaccine, Lassa Fever, CEPI, Themis

Themis Bioscience and CEPI the Coalition for Epidemic Preparedness Innovations announced today the first administration to healthy volunteers in a Phase 1 clinical trial with Themis vaccine candidate against Lassa fever.

Key Points: 
  • Themis Bioscience and CEPI the Coalition for Epidemic Preparedness Innovations announced today the first administration to healthy volunteers in a Phase 1 clinical trial with Themis vaccine candidate against Lassa fever.
  • The MV-LASV Lassa fever vaccine candidate, is based on Themis proprietary measles vector platform and exclusively-licensed discoveries made at Institut Pasteur.
  • Our partnership with CEPI for Lassa fever further validates our capabilities and represents our combined commitment to tackle diseases that remain a public health threat globally.
  • Dr. Melanie Saville, Director of Vaccine Development at CEPI added: Themis was the first company CEPI partnered with to develop a vaccine against Lassa fever and MERS, two of our priority pathogens.

Inovio Pharmaceuticals Reports 2018 Fourth Quarter and Year-End Financial Results

Retrieved on: 
Tuesday, March 12, 2019
Health, Medical specialties, Vaccination, Vaccine, Virology, Lassa fever, Pharmaceutical industry

PLYMOUTH MEETING, Pa., March 12, 2019 /PRNewswire/ --Inovio Pharmaceuticals, Inc. (NASDAQ:INO), a late-stage biotechnology company focused on the development and commercialization of DNA immunotherapies targeted against cancers and infectious diseases, today reported financial results for the fourth quarter and year ended December 31, 2018.

Key Points: 
  • PLYMOUTH MEETING, Pa., March 12, 2019 /PRNewswire/ --Inovio Pharmaceuticals, Inc. (NASDAQ:INO), a late-stage biotechnology company focused on the development and commercialization of DNA immunotherapies targeted against cancers and infectious diseases, today reported financial results for the fourth quarter and year ended December 31, 2018.
  • Inovio's management will host a live conference call and webcast at 4:30 p.m. Eastern Time today to discuss financial results and provide a general business update.
  • Inovio received IND approval for another CEPI funded vaccine for combatting Lassa fever, which will advance into the first human trial in the second quarter.
  • As of December 31, 2018, cash and cash equivalents and short-term investments were $81.2 million comparedto $85.5 million as of September 30, 2018.

Batavia Biosciences Partners with IAVI to Advance Development of Vaccine Against Lassa Fever

Retrieved on: 
Tuesday, December 11, 2018
Medicine, Microbiology, Tropical diseases, Health, Vaccines, Zoonoses, Lassa fever, RTT, Vesicular stomatitis virus, Lassa, International AIDS Vaccine Initiative, HIV vaccine

This process can facilitate rapid clinical development and establishment of a stockpile of an innovative new Lassa fever vaccine, which is based on the Vesicular Stomatitis Virus (VSV) vector system.

Key Points: 
  • This process can facilitate rapid clinical development and establishment of a stockpile of an innovative new Lassa fever vaccine, which is based on the Vesicular Stomatitis Virus (VSV) vector system.
  • Lassa fever, also known as Lassa hemorrhagic fever, is endemic in West Africa and can spread from person to person via contact with bodily fluids.
  • Batavia Biosciences' COO Dr Chris Yallop states: "It is an honor that IAVI has appointed Batavia Biosciences to partner in the development of such an innovative and potentially transformative vaccine production model."
  • IAVI's integrated capabilities in vaccine discovery, development, and clinical research take advantage of biopharmaceutical industry expertise to accelerate the development and testing of novel HIV vaccine candidates.

IAVI and the Public Health Agency of Canada Enter into License Agreement for Technology to Enable Lassa Fever Vaccine Development

Retrieved on: 
Thursday, August 2, 2018
Medicine, Health, Microbiology, Tropical diseases, Biological weapons, Zoonoses, Lassa fever, RTT, Coalition for Epidemic Preparedness Innovations, Lassa, Vesicular stomatitis virus, Vaccine

Through this agreement, IAVI obtained technology for a recombinant vesicular stomatitis virus (VSV) Lassa fever vaccine candidate, rVSVG-LASV-GPC.

Key Points: 
  • Through this agreement, IAVI obtained technology for a recombinant vesicular stomatitis virus (VSV) Lassa fever vaccine candidate, rVSVG-LASV-GPC.
  • With support from the Coalition for Epidemic Preparedness Innovations, the IAVI-led Lassa fever vaccine development program will further develop this candidate and create a stockpile to address future outbreaks.
  • An estimated 100,000 to 300,000 Lassa fever cases are diagnosed annually, resulting in approximately 5,000 deaths.
  • The World Health Organization (WHO) has identified Lassa fever as one of the top emerging pathogens likely to cause severe outbreaks in the near future.